<code id='44792B92B6'></code><style id='44792B92B6'></style>

<acronym id='44792B92B6'></acronym>

<center id='44792B92B6'><center id='44792B92B6'><tfoot id='44792B92B6'></tfoot></center><abbr id='44792B92B6'><dir id='44792B92B6'><tfoot id='44792B92B6'></tfoot><noframes id='44792B92B6'>

<optgroup id='44792B92B6'><strike id='44792B92B6'><sup id='44792B92B6'></sup></strike><code id='44792B92B6'></code></optgroup>

<b id='44792B92B6'><label id='44792B92B6'><select id='44792B92B6'><dt id='44792B92B6'><span id='44792B92B6'></span></dt></select></label></b><u id='44792B92B6'></u>

~~<i id='44792B92B6'><strike id='44792B92B6'><tt id='44792B92B6'><pre id='44792B92B6'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

hotspot

author：hotspot 2025-09-28 11:36:54 Page View：423

Franklin faces — Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Change Healthcare: What is it, why does its cyberattack matter?
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

Drug repurposing or repositioning? The language matters

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

1:45RandallMargraves,right,talkstoattorneyMickGrewal,ashepreparestostandinfrontofJudgeJaniceCunningh

Alkermes shareholders re

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

What to know about a major upcoming Wegovy heart health study

AdobeAtsomepointthissummer,thedrugmakerNovoNordiskwillreleaseresultsfromacloselywatchedstudythat,ifs

read more